On 3 April 2025, Chimeric extended the closing date of the Entitlement Offer to 5pm (Sydney time) on 22 April 2025. Chimeric received valid applications under the Entitlement Offer for 197,203,052 New Shares, raising an amount of approximately $1 million. 365 shareholders participated in the Entitlement Offer. Chimeric’s CEO Dr Rebecca McQualter said: “we are pleased with the continued support shown by shareholders in our recent rights issue. This additional funding provides us with further runway to progress our programs.” Issue and allotment of the New Shares and New Options will occur on 30 April 2025, and ASX trading of the New Shares and New Options is expected to commence on 1 May 2025. A shortfall of approximately 450,857,654 New Shares and 450,857,654 New Options (representing an amount of approximately $2.2 million) remains. The Company can place the shortfall in accordance with the ASX listing rules within 3 months of the closing date to the Entitlement Offer.
CHM Price at posting:
0.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)